Analyst Price Targets — SOPH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 15, 2026 10:36 am | — | BTIG | $8.00 | $4.96 | TheFly | Sophia Genetics price target raised to $8 from $7 at BTIG |
| March 3, 2026 7:23 pm | Mark Massaro | BTIG | $7.00 | $4.10 | StreetInsider | BTIG Reiterates Buy Rating on Sophia Genetics SA (SOPH) |
| January 26, 2026 2:36 pm | — | Guggenheim | $7.00 | $5.35 | TheFly | Sophia Genetics price target raised to $7 from $6 at Guggenheim |
| March 6, 2025 12:11 pm | — | BTIG | $5.00 | $3.11 | TheFly | Sophia Genetics price target lowered to $5 from $6 at BTIG |
| August 7, 2024 11:35 am | Tejas Savant | Morgan Stanley | $5.00 | $3.92 | TheFly | Sophia Genetics downgraded to Equal Weight from Overweight at Morgan Stanley |
| June 27, 2024 6:20 am | Subbu Nambi | Guggenheim | $6.00 | $4.52 | StreetInsider | Guggenheim Starts Sophia Genetics SA (SOPH) at Buy |
| January 3, 2023 7:14 am | Mark Massaro | BTIG | $6.00 | $2.06 | TheFly | Sophia Genetics initiated with a Buy at BTIG |
Latest News for SOPH
Shareholders adopt all proposals, co-founder Dr. Jurgi Camblong elected as Executive Chairman of the Board, Ross Muken elected as new member of the Board ahead of his appointment as CEO effective July 1, 2026 ROLLE, Switzerland, June 22, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today announced that its 2026 Annual General Meeting of shareholders adopted…
BOSTON and ROLLE, Switzerland, June 19, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the closing of its previously announced underwritten public offering with total gross proceeds of $57.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. As a result of strong investor…
SOPHiA GENETICS is approaching an inflection point in precision medicine, leveraging AI-driven genomic analysis as sequencing costs decline and data complexity rises. SOPH's platform benefits from a self-reinforcing data flywheel, with 2.5 million genomic profiles and 537 institutions using SOPHiA DDM across 75 countries. Revenue grew 22% year-over-year to $21.7M in 1Q26, with 117% net dollar retention and adjusted…
U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining over 100 points on Wednesday.
SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares PR Newswire BOSTON and ROLLE
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SOPH.
U.S. House Trading
No House trades found for SOPH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.